Background
Methods
Study design and setting
Participants
Data collection and management
Statistical analysis
Policy recommendation | Indicator |
---|---|
All key clinical features of severe malaria should be assessed and documented | Proportion among the children with a diagnosis of malaria with documented assessment of the following clinical features: level of consciousness (AVPU scale), deep acidotic breathing or chest in-drawing (respiratory distress), fever, ability to drink, convulsions and pallor |
All suspected malaria cases without a sign of severe disease should have parasitological confirmation by diagnostic testing before initiating treatment | Proportion of patients with a diagnosis of malaria with a malaria test ordered on the admission date and with the results recorded in the medical notes or laboratory register |
Malaria positive cases should be prescribed anti-malarial drug | Proportion with malaria positive test prescribed anti-malarials Proportion with malaria negative test prescribed anti-malarials Type of anti-malarial drugs prescribed |
Anti-malarial drug dosages; Quinine loading dose of 20 mg, maintenance dose of 10 mg and artesunate at 2.4 mg per kg body weight with a 20 % margin of error | Proportion with malaria positive prescribed quinine or artesunate and proportions with correct dosing |
Management of malaria negative; anti-malarial drugs should be withheld in non-severe malaria cases with a negative test; those with signs of severe malaria be started on presumptive treatment but testing should be repeated | Proportion of patients with admission diagnosis of severe malaria but a negative admission test and given anti-malarials who had repeat testing after admission |
Ethical consideration
Results
Malaria diagnosis and clinical features
Indicator | Overall | Hospitals | ||||
---|---|---|---|---|---|---|
H1 | H3 | H7 | H8 | H13 | ||
Number of malaria cases | 13014 | 2587 | 4572 | 1695 | 2563 | 1597 |
Male (%) | 6880/13014 (52.9) | 1388/2587 (53.7) | 2430/4572 (53.1) | 877/1695 (51.7) | 1361/2563 (53.1) | 824/1597 (51.6) |
Age in months, median (IQR) | 24 (12–36) | 20 (12–36) | 23 (12–36) | 20 (11–36) | 15 (9–27) | 24 (12–36) |
All clinical features documented | 9104/13014 (70.0) | 2013 (77.8) | 3169 (69.3) | 800 (47.2) | 2143 (83.6) | 979 (61.3) |
Malaria admissions with fevera (%) | 10063/10981 (91.6) | 2132/2255 (94.5) | 3527/3854 (91.5) | 1260/1317 (95.7) | 1890/2229 (84.8) | 1254/1326 (94.6) |
Malaria admissions with at least one danger signb (%) | 6427/13014 (49.4) | 1412/2587 (54.6) | 2204/4572 (48.2) | 675/1695 (39.8) | 1185/2563 (46.2) | 951/1597 (59.5) |
Altered level of consciousness (%) | 863/10600 (8.1) | 195/2160 (9.0) | 288/3828 (7.5) | 74/1227 (6.0) | 145/2201 (6.6) | 161/1184 (13.6) |
Inability to drink (%) | 1264/9514 (13.3) | 369/2111 (17.5) | 244/3370 (7.2) | 137/857 (16.0) | 272/2121 (12.8) | 242/1055 (22.9) |
Respiratory distress (%) | 1435/9692 (14.8) | 266/2161 (12.3) | 405/3373 (12.0) | 61/895 (6.8) | 539/2185 (24.7) | 164/1078 (15.2) |
Severe pallor (%) | 1583/10807 (14.6) | 383/2180 (17.6) | 795/3848 (20.7) | 171/1281 (13.3) | 103/2202 (4.7) | 131/1296 (10.1) |
Convulsions (%) | 3699/10625 (34.8) | 775/2205 (35.1) | 1227/3721 (33.0) | 427/1196 (35.7) | 555/2223 (25.0) | 715/1280 (55.9) |
Investigation of admissions with clinical malaria
Indicator | Overall | H1 | H3 | H7 | H8 | H13 |
---|---|---|---|---|---|---|
Total malaria admissions (N) | 13014 | 2587 | 4572 | 1695 | 2563 | 1597 |
Malaria investigations
| ||||||
Proportion with malaria test requested, n/N (%) | 11981/13014 (92.0) | 2533/2587 (97.9) | 3770/4572 (82.5) | 1596/1695 (94.2) | 2505/2563 (97.7) | 1577/1597 (98.7) |
Malaria test results available, n/N (%) | 10388/11981 (86.7) | 2516/2533 (99.3) | 2510/3770 (66.6) | 1481/1596 (92.8) | 2327/2505 (92.9) | 1554/1577 (98.5) |
Positive malaria test in those with results documented, n/N (%) | 8050/10388 (77.5) | 1902/2516 (75.6) | 2046/2510 (81.5) | 1162/1481 (78.5) | 1609/2327 (69.1) | 1331/1554 (85.6) |
Positive malaria test in all children diagnosed with malaria, n/N (%) | 8050/13014 (61.9) | 1902/2587 (73.5) | 2046/4572 (44.8) | 1162/1695 (68.6) | 1609/2563 (62.8) | 1331/1597 (83.3) |
Diagnosis of severe malaria with positive test, n/N (%) | 5243/8050 (65.1) | 1174/1902 (61.7) | 1701/2046 (83.1) | 699/1162 (60.2) | 793/1609 (49.3) | 876/1331 (65.8) |
Antimalarial prescription
| ||||||
Proportion with positive test prescribed anti-malarial drug, n/N (%) | 6745/8050 (83.8) | 1642/1902 (86.3) | 1760/2046 (86.0) | 909/1162 (78.2) | 1347/1609 (83.7) | 1087/1331 (81.7) |
Proportion with negative test prescribed anti-malarial drug, n/N (%) | 1613/2338 (69.0) | 479/614 (78.0) | 372/464 (80.2) | 169/319 (53.0) | 445/718 (62.0) | 148/223 (66.4) |
Proportion of negative test treated presumptively with repeat testing, n/N (%) | 52/1613 (3.2) | 7/479 (1.5) | 0 | 1/169 (0.6) | 18/445 (4.0) | 26/148 (17.6) |
Proportion with no malaria test treated presumptively, n/N (%) | 786/1033 (76.1) | 28/54 (51.9) | 674/802 (84.0) | 45/99 (45.5) | 35/58 (60.3) | 4/20 (20.0) |
Antibiotic prescription
| ||||||
Proportion of all malaria admission cases prescribed antibioticsa, n/N (%) | 6966/13014 (53.5) | 1428/2587 (55.2) | 2615/4572 (57.2) | 609/1695 (35.9) | 1555/2563 (60.7) | 759/1597 (47.5) |
Proportion with positive test prescribed antibioticsa, n/N (%) | 4041/8050 (50.2) | 1025/1902 (53.9) | 1122/2046 (54.8) | 369/1162 (31.8) | 920/1609 (57.2) | 605/1331 (45.5) |
Proportion with negative prescribed antibioticsa, n/N (%) | 1463/2338 (62.6) | 368/614 (59.9) | 290/464 (62.5) | 172/319 (53.9) | 497/718 (69.2) | 136/223 (61.0) |
Treatment of malaria cases
Type of anti-malarial | Overall (n = 6745) (%) | Hospitals | ||||
---|---|---|---|---|---|---|
H1 (n = 1642) (%) | H3 (n = 1760) (%) | H7 (n = 909) (%) | H8 (n = 1347) (%) | H13 (n = 1087) (%) | ||
Quinine | 3184 (47.2) | 1075 (65.5) | 946 (53.8) | 587 (64.9) | 13 (1.0) | 563 (51.8) |
Artesunate | 3108 (46.1) | 478 (29.1) | 739 (42.0) | 244 (26.8) | 1199 (89.0) | 448 (41.2) |
Quinine and artesunate | 158 (2.3) | 56 (3.4) | 26 (1.5) | 54 (5.9) | 2 (0.2) | 20 (1.8) |
Coartem (Artemether-lumefantrine) | 250 (3.7) | 33 (2.0) | 18 (1.0) | 19 (2.1) | 124 (9.2) | 56 (5.2) |
Other anti-malarialsa
| 45 (0.7) | 0 | 31 (1.8) | 5 (0.6) | 9 (0.7) | 0 |